Contact Us

News

Press Releases

SanegeneBio Announces FDA Orphan Drug Designation for SGB-9768 for the Treatment of IC-MPGN

SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech

SanegeneBio Announces First Patient Dosed in Phase 1 Trial of SGB-7342

SanegeneBio Receives NMPA Approval to Initiate Clinical Trials of SGB-7342 for Obesity

SanegeneBio Raises over $110 Million in Series B Financing

SanegeneBio Announces Phase 1 Clinical Data for SGB-9768 Presented at ASN Kidney Week 2025

SanegeneBio and Innovent Announce Phase 1 Clinical Data for SGB-3908 Presented at American Heart Association (AHA) 2025 Annual Meeting

SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly

SGB-9768 Clinical Data to be Reported at ASN Kidney Week 2025

SanegeneBio Announces FDA Orphan Drug Designation for SGB-9768, an Experimental RNAi Medicine Targeting C3 mRNA

Load More
Contact Us